The reimbursement environment for diagnostics company LipoScience (LPDX)
is not going to change in a quarter's time and with that, neither will
the commercial/financial situation change all that much. LipoScience
remains what it has been for some time - a company with a very
interesting cholesterol test, one that measures the actual number of
cholesterol particles and not just the overall amount of cholesterol in
the blood, but a company that definitely needs to sell payers and
clinicians on the importance of this test and its role in health care
management.
If LipoScience can accumulate and present the data
necessary to sway insurance companies and doctors, $100 million in
annual revenue in five years' time and $200 million in 10 years' time
should be sufficient to justify a stock price closer to $8 today.
Unfortunately, it's quite difficult to get institutions excited about a
small-cap med-tech stock reporting contracting revenue and that has seen
recent executive turnover. Readers thinking about LipoScience as an
investment need to realize that this is both an above-average risk
situation and one where patience will be required.
Read the full article at Seeking Alpha:
The LipoScience Holding Pattern Continues
No comments:
Post a Comment